IIn Vitro/I Drug Susceptibility of a ILeishmania infantum/I Isolate from a Visceral Leishmaniasis Pediatric Patient after Multiple Relapses

• Published in: Tropical medicine and infectious disease 2023-07, Vol.8 (7)
• Main Authors: Ferreira, Bianca A, Santos, Gustavo de A, Coser, Elizabeth M, Sousa, Juliana M, Gama, Mônica E. A, Júnior, Leônidas L. B, Pessoa, Fabrício S, Lima, Mayara I. S, Uliana, Silvia R. B, Coelho, Adriano C
• Format: Article
• Language: English
• Subjects: Cancer; Chemotherapy; Children; Drugs; Health aspects; Kala-azar; Medical research; Medicine, Experimental; Pediatrics
• ISSN: 2414-6366; 2414-6366
• DOI: 10.3390/tropicalmed8070354

The parasitic protozoan Leishmania (Leishmania) infantum is the etiological agent of human visceral leishmaniasis in South America, an infectious disease associated with malnutrition, anemia, and hepatosplenomegaly. In Brazil alone, around 2700 cases are reported each year. Treatment failure can occur as a result of drug, host, and/or parasite-related factors. Here, we isolated a Leishmania species from a pediatric patient with visceral leishmaniasis that did not respond to chemotherapy, experiencing a total of nine therapeutic relapses and undergoing a splenectomy. The parasite was confirmed as L. (L.) infantum after sequencing of the ribosomal DNA internal transcribed spacer, and the clinical isolate, in both promastigote and amastigote forms, was submitted to in vitro susceptibility assays with all the drugs currently used in the chemotherapy of leishmaniasis. The isolate was susceptible to meglumine antimoniate, amphotericin B, pentamidine, miltefosine, and paromomycin, similarly to another strain of this species that had previously been characterized. These findings indicate that the multiples relapses observed in this pediatric patient were not due to a decrease in the drug susceptibility of this isolate; therefore, immunophysiological aspects of the patient should be further investigated to understand the basis of treatment failure in this case.